Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Litton

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
International Journal of Radiation Oncology, Biology, Physics|August 15, 2024
PRECISE: Preoperative Radiation Therapy to Elicit Critical Immune Stimulating Effects-A Phase 2 Clinical TrialSimona F Shaitelman, Huong Le-Petross, Maria G Raso, et al.
Breast Cancer Research and Treatment|June 1, 2026
Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trialKamaria L Lee, Clinton Yam, Li Zhao, et al.
JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.
Breast Cancer Research and Treatment|April 24, 2020
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrenceTommy A Brown, Elizabeth A Mittendorf, Diane F Hale, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017Mary B Daly, Robert Pilarski, Michael Berry, et al.
Radiology. Imaging Cancer|July 28, 2023
A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast CancerKen-Pin Hwang, Nabil A Elshafeey, Aikaterini Kotrotsou, et al.
Cell Reports|May 16, 2025
The impact of breast radiotherapy on the tumor genome and immune ecosystemAislyn Schalck, Tuan Tran, Jianzhuo Li, et al.
Scientific Reports|July 11, 2024
Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerRania M Mohamed, Bikash Panthi, Beatriz E Adrada, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
International Journal of Radiation Oncology, Biology, Physics|August 15, 2024
PRECISE: Preoperative Radiation Therapy to Elicit Critical Immune Stimulating Effects-A Phase 2 Clinical TrialSimona F Shaitelman, Huong Le-Petross, Maria G Raso, et al.
Breast Cancer Research and Treatment|June 1, 2026
Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trialKamaria L Lee, Clinton Yam, Li Zhao, et al.
JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.
Breast Cancer Research and Treatment|April 24, 2020
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrenceTommy A Brown, Elizabeth A Mittendorf, Diane F Hale, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017Mary B Daly, Robert Pilarski, Michael Berry, et al.
Radiology. Imaging Cancer|July 28, 2023
A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast CancerKen-Pin Hwang, Nabil A Elshafeey, Aikaterini Kotrotsou, et al.
Cell Reports|May 16, 2025
The impact of breast radiotherapy on the tumor genome and immune ecosystemAislyn Schalck, Tuan Tran, Jianzhuo Li, et al.
Scientific Reports|July 11, 2024
Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerRania M Mohamed, Bikash Panthi, Beatriz E Adrada, et al.
Pageof 16